SCHEMBL25613105

SCHEMBL25613105

CC(C)(C)c1cc2cc[nH]c2nc1OCC1CCS(=O)(=O)C1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ JAK2 O60674 1/20 0.35
▸ ALDH1A1 P00352 2/20 0.33
▸ HSD17B10 Q99714 1/20 0.33
▸ HTR5A P47898 1/20 0.33
▸ CNR2 P34972 5/20 0.33
▸ JAK1 P23458 2/20 0.32
▸ MAPK8 P45983 1/20 0.31
▸ MAPK9 P45984 1/20 0.31
▸ MAPK10 P53779 1/20 0.31
▸ FEN1 P39748 1/20 0.31
▸ CCNT1 O60563 1/20 0.31
▸ CDK1 P06493 1/20 0.31
▸ CCNB1 P14635 1/20 0.31
▸ CDK2 P24941 1/20 0.31
▸ CDK7 P50613 1/20 0.31
▸ CDK9 P50750 1/20 0.31
▸ CCNH P51946 1/20 0.31
▸ CDK5 Q00535 1/20 0.31
▸ MAPT P10636 1/20 0.30
▸ CHRNA7 P36544 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25613106 0.91 FEN1 (0.33) ALDH1A1CNR2FEN1CCNT1CDK1
SCHEMBL25613092 0.83 CDK2 (0.40) CCNT1CDK1CCNB1CDK2CDK7
SCHEMBL25613094 0.83 CDK2 (0.38) CNR2FEN1CCNT1CDK1CCNB1
SCHEMBL25613187 0.81 GRM4 (0.35) JAK1FEN1
SCHEMBL25613097 0.78 CHRNB4 (0.39) —
SCHEMBL25613088 0.77 GRM4 (0.40) JAK2CNR2JAK1CCNT1CDK1
SCHEMBL25613190 0.76 CTSD (0.32) ALDH1A1FEN1MAPT
SCHEMBL25613103 0.75 CHRNA3 (0.42) CDK5
SCHEMBL25613093 0.75 CHRNA3 (0.42) —
SCHEMBL25613037 0.74 FEN1 (0.39) FEN1CDK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230159527-A1 COMPOUNDS AS BCL-2 INHIBITORS FOCHON BIOSCIENCES, LTD. (CN) 2023-05-25 — — US disclosed
US-20230159527-A1 COMPOUNDS AS BCL-2 INHIBITORS FOCHON BIOSCIENCES, LTD. (CN) 2023-05-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230159527-A1 COMPOUNDS AS BCL-2 INHIBITORS BCL2, BCL2L2, BCL2L1 JAK2 431/4885ALDH1A1 3019/4885HSD17B10 1216/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback